ResearcherAristotle University of ThessalonikiActive in the last 2 years
George Fountzilas
Matched on ORCID iD 0000-0001-8045-2186; OpenAlex author ID A5028090273, A5041575636. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 12
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACI… Co-author DOI 10.1016/j.ctarc.2026.101481↗
- Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers13020198↗
- Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents ta… Co-author DOI 10.1136/esmoopen-2019-000525↗
- Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Gr… Last author DOI 10.1007/s11523-018-0605-y↗
- Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. Last author DOI 10.21873/anticanres.11232↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- George E. Pentheroudakis · 4 shared papers, 2016–2026 · strength 0.44
- Paper Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with … DOI 10.1016/j.ctarc.2026.101481↗
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- George Papaxoinis · 3 shared papers, 2016–2026 · strength 0.39
- Paper Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with … DOI 10.1016/j.ctarc.2026.101481↗
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Paper Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. DOI 10.21873/anticanres.11232↗
- Elena Fountzilas · 2 shared papers, 2021–2026 · strength 0.34
- Paper Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with … DOI 10.1016/j.ctarc.2026.101481↗
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Christos Dervenis · 4 shared papers, 2016–2021 · strength 0.28
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- Dimitrios G. Pectasides · 4 shared papers, 2016–2021 · strength 0.28
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- Ioannis Kotsantis · 1 shared paper, 2026 · strength 0.25
- George Zarkavelis · 2 shared papers, 2019–2021 · strength 0.16
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Vasilios Karavasilis · 2 shared papers, 2018–2019 · strength 0.14
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- Georgios Oikonomopoulos · 1 shared paper, 2021 · strength 0.09
- Nikolaos K. Kentepozidis · 1 shared paper, 2021 · strength 0.09
- Philippos C. Patsalis · 1 shared paper, 2021 · strength 0.09
- Christos Agalianos · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.